EACS2023: 728 Experience with the use of prolonged-release injectable CAB/RPV in outpatients N. Bobbio , E. Blasi Vacca , S. Boni , F. Del Puente , M. Feasi , A. Parisini , R. Prinapori , S. Tigano , F. Filauro , B. Mainero , A. Zunino , C. Fraguglia , E. Pontali Galliera Hospital, Infectious Diseases, Genoa, Italy, Galliera Hospital, Pharmacy, Genoa, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Since November 2022 we started to use cabotegravir+rilpivirine (CAB/RPV) at our hospital.The aim of this work is to describe our experience during the last 8 months. Method: We prospectively collected data (epidemiological, immunovirological staging, blood chemistry tests, safety) of patients (pts) who received CAB/RPV, initially orally (28 days) and subsequently IM. Results: 32 pts were observed, mostly males (84%); mean age 45 years; mean BMI 24; HIV acquisition: 11 HE (34%), 20 MSM (62%), 1 IDU (4%). 13 pts (41%) had metabolic co-morbidities, such as diabetes, overweight, arterial hypertension, dyslipidemia. Their previous ARV regimen was triple ARV:19 pts (59.5%), oral dual ARV: 13 pts (40.5%). All pts had HIV-RNA<14 cp/ml at start of oral intake.At first CAB/RPV-IM HIV-RNA was <14 cp/ml in 30 pts (94%), 2 pts had viral blips (HIVRNA<40cp/ml). At the second CAB/RPV-IM all 30 pts had HIV-RNA<14 cp/ml. 5 pts discontinued CAB/RPV: one pt due to fever and arthralgias occurring three days after the first CAB/RPV-IM (Injection Site Reaction-ISR);one pt due to allergic rash (although unrelated) occurring three days after the first CAB/RPV-IM;one pt to the onset of acute pancreatitis (it required hospitalization) 4 days after the first CAB/RPV-IM (although unrelated);one pt for ISR after the second CAB/RPV-IM;one pt for ISR after the third CAB/RPV-IM. 20 pts received the third CAB/RPV-IM; 19 pts had HIV-RNA<14 cp/ml, 1 pt had viral blip <70 cp/ml. 12 pts received the fourth CAB/RPV-IM, 11 pts had HIV-RNA<14 cp/ml, 1 pt had viral blip <40 cp/ml Conclusions: Despite the need for larger cohorts with a longer observation time, our work shows that ARV injection therapy with CBV/RPV has excellent virological efficacy while maintaining viral suppression. We also observed 5 cases of therapy interruption (3 ISRs), greater experience with these drugs will be essential to better evaluate their tolerability in real world settings. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 1 2 2 2 2 1 1 2 150 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=